Document:

Exhibit

November 3, 2016

Mr. John L. Knopf, Ph.D.

Dear John:

Thank you for agreeing to become chair of the Scientific Advisory Board of Acceleron Pharma Inc. (the “Company”).  This letter (this “Agreement”) confirms the terms of your engagement to provide certain consulting services to the Company as chair of the Scientific Advisory Board.  We have agreed as follows: 
1.    Services.  You agree to serve as chair of the Company’s Scientific Advisory Board and provide consulting services to the Company in that capacity. You agree to use reasonable efforts to attend (or participate in by telephone) regularly scheduled meetings of the Scientific Advisory Board.  Unless otherwise mutually agreed by you and the Company, the aggregate time required of you for consulting services and Scientific Advisory Board meeting attendance is expected to not exceed one and a half (1.5) days per week.  You will use commercially reasonable efforts in rendering services to and promoting the best interests of the Company.
2.    Term.  Your membership on the Scientific Advisory Board shall commence on December 1, 2016 and continue until terminated in accordance with this Section.  Either of us may terminate your membership on the Scientific Advisory Board at any time, with or without reason or cause, by giving written notice to the other.  
3.    Expenses.  We will reimburse you for reasonable and necessary expenses which are incurred in connection with your performance of the services and obligations hereunder and with respect to which you promptly provide to us a detailed expense account and receipts, provided that any expenses (other than reasonable travel expenses incurred in connection with attendance at a meeting of the Scientific Advisory Board in accordance with Company policy) have been approved by the Company in advance and in writing.  Notwithstanding anything to the contrary herein: (i) the amount of expenses eligible for reimbursement or in-kind benefits provided to you during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to you in any other calendar year, (ii) the reimbursements for expenses for which you are entitled to be reimbursed will be made within thirty (30) days following the Company’s receipt of your detailed expense account and receipts, and in all events on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred and (iii) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.

4.    Consulting Fees and Treatment of Equity.  
(a)    In exchange for all of the services that you provide to the Company under this Agreement, during the term of this Agreement the Company will pay you a consulting fee at the rate of $100,000.00 per year, prorated for any partial year.  All consulting fees paid hereunder will be payable on a quarterly basis.  
(b)    A schedule of the outstanding and unvested options to purchase common stock of the Company (“Options”) and restricted stock units with respect to common stock of the Company  (“RSUs”) that you hold as of December 1, 2016 is attached hereto as Exhibit A.  You acknowledge and agree that Exhibit A contains a true and correct list of Company outstanding and unvested equity awards held by you as of the date hereof.  Consistent with the terms of the Acceleron Pharma Inc. 2013 Equity Incentive Plan (the “Plan”) and the applicable award agreements thereunder evidencing Options (the “Option Awards”), any outstanding and unvested Options that you hold as of the date of this Agreement will continue to vest in accordance with their terms so long as you continue to serve as a member of the Scientific Advisory Board.  In accordance with the terms of the Option Awards, following the termination of your service as a member of the Scientific Advisory Board without Cause (as defined in the Option Awards), you will have three months (or until the Final Exercise Date, as defined in the Option Awards, if sooner) to exercise any vested Options.  Likewise, consistent with the terms of the Plan and the award agreements evidencing the grant by the Company of  RSUs on each of September 9, 2015 and March 3, 2016), the RSUs held by you on the date of this Agreement will continue to vest in accordance with their terms so long as you continue to serve as a member of the Scientific Advisory Board; provided, however, that if your service as a member of the Scientific Advisory Board is terminated by the Company or its Affiliates on or prior to the Initial Vesting Date without Cause and in the absence of any Cause Circumstances (as such terms are defined in the Restricted Stock Unit Award Agreement between the Company and you with respect to RSUs granted on September 9, 2015 (the “2015 Restricted Stock Unit Agreement”)), any RSUs evidenced by such 2015 Restricted Stock Unit Agreement previously determined to have become Earned Units (as such term is defined in the 2015 Restricted Stock Unit Agreement) shall vest immediately upon such termination.  For the avoidance of doubt, except as otherwise provided herein, no Options or RSUs held by you will vest in connection with or following the termination of your service as a member of the Scientific Advisory Board.  You acknowledge and agree that upon a change in control of the Company, any outstanding Options and RSUs that you then hold will governed by the terms of the Plan and, in the case of RSUs evidenced by the 2015 Restricted Stock Unit Agreement, Section 2(c) of such agreement.
5.    Confidential Information.
(a)    You recognize and acknowledge that all technology, methods, systems, patents and patent applications, procedures, manuals, confidential reports, financial information, know-how, techniques, discoveries, Inventions (as defined below), reagents, chemical compounds, cell lines or subcellular constituents, organisms, or other biological materials, trade secrets, software, processes, algorithms, ideas, business strategies, business plans, prospects, or opportunities, customer information, personnel information, and other confidential or proprietary information, in tangible and intangible form, of and relating to the Company and its businesses, customers, suppliers, 

2

investors and other associated third parties (“Confidential Information”) that you may receive, learn, develop or otherwise acquire in the course of providing services to the Company are valuable assets of the Company, the use or disclosure of which would cause the Company substantial loss and damage which could not be readily calculated and for which no remedy at law would be adequate.  Confidential Information also includes other information that is marked or otherwise identified as confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is known or used.  Accordingly, you agree at all times, both during and after the term of this Agreement, not to disclose or use, directly or indirectly, any such Confidential Information, except as necessary in connection with your provision of services to the Company under this agreement.  Confidential Information shall not include any information that is known or becomes generally known or available publicly other than as a result of disclosure by you that is not permitted, or the Company discloses to others without obtaining an agreement of confidentiality.  You also agree that you may be required by the Company to execute a confidentiality agreement with a third party to protect such party’s confidential information as governed by an agreement between the Company and the third party.
(b)    Nothing in this Section 5 shall prohibit you from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. You shall not need the prior authorization of the Company’s General Counsel to make any such reports or disclosures and you are not required to notify the Company that you have made such reports or disclosures. You shall only disclose that Confidential Information which is necessary for such report or disclosure. In addition, you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to attorney, and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, so long as such filing is made under seal.
6.    Assignment of Rights to Intellectual Property.  You agree to promptly and fully disclose and assign, and hereby assign, to the Company (or as otherwise directed by the Company) all of your rights, title and interest in and to all inventions, original works of authorship, improvements, modifications, discoveries, technologies, biological materials, technical data, know-how, developments, methods, processes, works, compositions, concepts and ideas (whether or not patentable or copyrightable or constituting trade secrets) conceived, created, developed or reduced to practice by you (whether alone or with others), solely in the performance of your services on the Scientific Advisory Board or in the course of providing consulting services that relate to any present or proposed activity of the Company or that result from any services performed by you for the Company or any of its affiliates or that make use of Confidential Information or any of the equipment or facilities of the Company or any of its affiliates (the “Inventions”).  You agree to execute any and all applications for domestic and foreign patents, copyrights or other proprietary rights and to do such other acts (including without limitation the execution and delivery of instruments of further assurance or confirmation) requested by the Company to assign the Inventions to the Company (or as otherwise directed by the Company) and to permit the Company to enforce any patents, copyrights 

3

or other proprietary rights to the Inventions.  Your obligation to assist the Company in obtaining and enforcing patents and other intellectual property rights on Inventions in any and all countries shall continue beyond the termination of your services hereunder, but the Company shall compensate you at a reasonable, standard hourly rate following such termination for time directly spent by you at the Company’s request for such assistance.
7.    Non-Competition & Non-Solicitation.  
(a)    You agree that during your service on the Scientific Advisory Board and for a period of twelve (12) months immediately following termination of your service on the Scientific Advisory Board (the “Restricted Period”) you shall not directly or indirectly, either alone or in association with others, engage, assist others in engaging, participate or invest, in any business activity, business, or enterprise (whether as an officer, director, owner, partner, employee, promoter, consultant, manager, stockholder other than as the holder of less than 1% of the outstanding stock of any publicly traded company, or otherwise), that is competitive with or similar to the therapeutic, diagnostic or biological products or services of the Company, whether or not such products or services are in development or commercialized (including but not limited to any business or enterprise that researches, develops, manufactures, sells or otherwise provides any such therapeutic, diagnostic or biological product or service that competes with any therapeutic, diagnostic or biological product or service researched, developed, manufactured, sold, or otherwise provided, or planned to be researched, developed, manufactured, sold or otherwise provided by the Company while you were employed or engaged by the Company).  
(b)    You agree that during the Restricted Period you will not, whether for your own account or for the account of any other person (excluding the Company): (i) solicit or contact in an effort to do business with any person or entity who was or is a customer of the Company during the term of this Agreement or after its termination, or any affiliate of any such person or entity, if such solicitation or contact is for the purpose of competition with the Company; or (ii) solicit or induce any of the Company’s employees or contractors to leave their employment or other relationship with the Company or accept employment with any other person or entity, or hire or engage any such employees.
8.    Acknowledgment.  You acknowledge that you have carefully read and considered the provisions of Sections 5, 6 and 7 of this Agreement (including the Restricted Period and scope of activity to be restrained) to be fair and reasonable and reasonably required for the protection of the interests of the Company, its officers, directors, employees, creditors, and shareholders.  You agree that any breach by you of Sections 5, 6 or 7 of this Agreement would cause irreparable harm to the Company and you therefore further agree that the Company shall, in addition to any other remedies available to it, be entitled to preliminary and permanent injunctive relief against any breach by you of the covenants contained in Sections 5, 6 and 7, without having to post bond.  If any provision of this Agreement shall be declared invalid, illegal, or unenforceable, then such provision shall be enforceable to the extent that a court deems it reasonable to enforce such provision.
9.    Independent Contractor.  

4

(a)    It is agreed that you will perform your services to the Company as an independent contractor and that nothing in this Agreement shall in any way be construed to give rise to an employment relationship between you and the Company.  You will be solely responsible for determining the method, details and means of performing the Services.  You are free to accept engagements from others during the term of this Agreement, as long as those engagements do not interfere with you providing services under this Agreement or otherwise violate any of your obligations hereunder.  
(b)    You will have no authority to enter into contracts that bind the Company or any of its affiliates or create obligations on the part of the Company or any of its affiliates without the prior written authorization of the Company.  You will have full responsibility for applicable taxes for all compensation paid to you under this Agreement, and for compliance with all applicable labor and employment requirements with respect to your self-employment, including state worker’s compensation insurance coverage requirements.  Because you are an independent contractor, neither you nor any dependent or other individual claiming through you will be eligible to participate in, or receive benefits under, any of the employee benefit plans maintained by the Company, other than any rights you may have to continue participation in the Company’s group medical plans under the federal law known as COBRA.  You hereby waive all rights to participate in, or receive benefits under, any of the Company’s plans, other than pursuant to COBRA.  You agree to indemnify and hold harmless the Company and its affiliates and their respective plans, shareholders, directors, officers, employees, agents, successors and assigns, from any and all losses, costs and expenses, including without limitation attorneys’ fees, and any other liabilities incurred by any of the foregoing as a result of a failure by you to meet your obligations under this Section 9(b) or in any way arising out of any claim by you or by anyone claiming through you under any Company plan (other than in exercising your rights pursuant to COBRA).  Notwithstanding the foregoing, nothing herein will affect your rights to distribution of any vested funds in your 401(k) account.
10.    Representations; Consent.  You represent and warrant that you have no commitments or obligations inconsistent with this Agreement or that would in any way restrict your activities as chair of the Scientific Advisory Board.  You consent to being named as an advisor or as a member or chair of the Scientific Advisory Board in press releases, offering documents, reports or other documents in printed or electronic form, and any documents filed with the Securities and Exchange Commission.  The Company will refer to you as chair of the Scientific Advisory Board in any such documents where your involvement with the Scientific Advisory Board is referenced for so long as you hold such position.
11.    Miscellaneous.  This Agreement constitutes the entire understanding of the parties with respect to the subject matter hereof and supersedes all prior or current communications, understandings and agreements, whether written or oral, with respect to such subject matter, including the letter agreement dated August 26, 2013 between you and the Company, and excluding only the Employee Confidentiality, Non-Compete and Proprietary Information Agreement between you and the Company dated March 4, 2016, the Option Awards, the 2015 Restricted Stock Unit Agreement, the Restricted Stock Unit Award Agreement between the Company and you with respect to RSUs granted on March 3, 2016 and the Plan, which shall all remain in full force and effect in accordance with their terms.  Any term of this Agreement may be amended or waived only with 

5

the written consent of the parties.  The invalidity or unenforceability of any provision hereof shall not affect the validity and enforceability of any other term or provision hereof.  You may not assign your rights or delegate your responsibilities under this Agreement without our prior written consent.  The provisions of Sections 5, 6, 7 and 8 will survive termination or expiration of this Agreement.  This Agreement shall be governed by and construed in accordance with the laws (other than the conflict of laws principles) of the Commonwealth of Massachusetts.  
Again, thank you for agreeing to become chair of our Scientific Advisory Board.  We look forward to working with you and believe that your service will be significant to the long-term success and viability of the Company.  If this letter accurately sets forth our agreement, please so indicate by signing below on both copies of this letter and returning both to us.  We will forward to you a fully executed Agreement for your files.
Very truly yours,

ACCELERON PHARMA INC.

By: /s/ Joseph S. Zakrzewski    
Name: Joseph S. Zakrzewski
Title: Compensation Committee Chair

Agreed and Accepted:

/s/ John L. Knopf    
Name:  John L. Knopf
Date:  November 3, 2016    

6

EXHIBIT A

ACCELERON PHARMA INC.
PERSONNEL VESTING SUMMARY
AS OF DECEMBER 1, 2016
JOHN L. KNOPF

	
																					
	ID
	 
	

Type
	 
	Grant Number
	 
	Grant Date
	 
	

Plan
	 
	Shares
	 
	Price
	 
	Total Unvested

	1
	 
	ISO
	 
	839
	 
	12/05/2013
	 
	2013
	 
	4,147
	 
	$24.1100
	 
	4,147

	 
	 
	NQ
	 
	840
	 
	12/05/2013
	 
	2013
	 
	105,853
	 
	$24.1100
	 
	30,228

	 
	 
	NQ
	 
	992
	 
	01/08/2015
	 
	2013
	 
	151,000
	 
	$41.2000
	 
	84,937

	 
	 
	NQ
	 
	1174
	 
	03/03/2016
	 
	2013
	 
	105,000
	 
	$27.9700
	 
	85,312

	 
	 
	PSU
	 
	1145
	 
	09/09/2015
	 
	2013
	 
	89,000
	 
	$0.0000
	 
	89,000

	 
	 
	RSU
	 
	1469
	 
	03/03/2016
	 
	2013
	 
	17,500
	 
	$0.0000
	 
	17,500

	TOTAL
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	311,124Exhibit 10.1

 

AMENDED AND RESTATED EXCHANGE AGREEMENT

 

AMENDED AND RESTATED
EXCHANGE AGREEMENT (the “Agreement”) is made as of the 2nd day of November 2016, by and between, Great Basin
Scientific, Inc., a Delaware corporation (the “Company”), and the investor signatory hereto (the “Investor”).

 

WHEREAS, reference
is hereby made to (a) that certain Securities Purchase Agreement, dated December 28, 2015, by and among the Company, the Investor
and certain other buyers signatory thereto (the “2015 SPA”), pursuant to which the Investor and such other buyers
acquired (i) senior secured convertible notes issued pursuant to the 2015 SPA (the “2015 Notes”) and (ii) warrants
to acquire shares of the Company's common stock, par value $0.0001 per share (the ”Common Stock”) issued
pursuant to the 2015 SPA (the “2015 Warrants”), (b) that certain Securities Purchase Agreement, dated June 29,
2016, by and among the Company, the Investor and certain other buyers signatory thereto (the “2016 SPA” and
together with the 2015 SPA, each, an “SPA” and collectively, the “SPAs”), pursuant to which
the Investor and such other buyers acquired (i) senior secured convertible notes issued pursuant to the 2016 SPA (the “2016
Notes”) and (ii) warrants to acquire shares of Common Stock issued pursuant to the 2016 SPA (the “2016 Warrants”),
(c) that certain amended and restated leak-out agreement, dated October 17, 2016, by and between the Company and the Investor (the
“Leak-Out Agreement”) and (d) that certain Exchange Agreement, dated October 2, 2016, by and between the Company
and the Investor (the “Original Exchange Agreement”). Capitalized terms not defined herein shall have the meaning
as set forth in the 2015 SPA and/or 2015 Notes, as applicable.

 

WHEREAS, the
parties hereto desire to amend and restate the Original Exchange Agreement as provided herein.

 

WHEREAS, the
Company has authorized a new series of convertible Preferred Stock of the Company designated as Series F Convertible Preferred
Stock, $0.001 par value, the terms of which are set forth in the Certificate of Designations for such series of Preferred Stock
(the “Certificate of Designations”) in the form attached hereto as Exhibit A (together with any
convertible preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series F Preferred
Stock”), which Series F Preferred Stock shall be convertible into shares of Common Stock (such shares of Common Stock
issuable pursuant to the terms of the Certificate of Designations, including, without limitation, upon conversion or otherwise,
collectively, the “Preferred Conversion Shares”), in accordance with the terms of the Certificate of Designations.

 

WHEREAS, in
exchange for the aggregate principal amount of the 2015 Notes outstanding as of the Closing Date (as defined below) (together with
any accrued and unpaid interest thereon and late charges, if any, on such principal and interest, the “Exchange Note”,
and such aggregate outstanding amount thereunder, the “Exchange Note Amount”), the Company desires to issue
to the Investor, such aggregate number of shares of Series F Preferred Stock (the “Preferred Shares”) equal
to the quotient of (x) the Exchange Note Amount, divided by (y) $1,000 (rounded up to the nearest whole share), all as set forth
on the Investor's signature page attached hereto.

 

     

     

    

 

WHEREAS, the
exchange of the Exchange Note for the Preferred Shares is being made in reliance upon the exemption from registration provided
by Section 4(a)(2) and Rule 144(d)(3)(ii) of the Securities Act of 1933, as amended (the “1933 Act”).

 

WHEREAS, concurrently
herewith, the Company is entering into agreements with holders of 2015 Notes representing at least the Required Holders (as defined
in the 2015 Notes) (each, an “Other Investor”, and such agreements, each an “Other Agreement”)
substantially in the form of this Agreement (other than with respect to the identity of the Investor, any provision regarding the
reimbursement of legal fees and proportional changes reflecting the different aggregate principal amount of the 2015 Notes of such
Other Investor then outstanding).

 

NOW, THEREFORE,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in consideration of the
promises and the mutual agreements, representations and warranties, provisions and covenants contained herein, the parties hereto,
intending to be legally bound hereby, agree as follows:

 

1.       Exchange.
On the Closing Date, subject to the terms and conditions of this Agreement, the Investor shall, and the Company shall,
pursuant to Section 4(a)(2) and Rule 144(d)(3)(ii) of the 1933 Act, exchange the Exchange Note for the Preferred Shares. At
the Closing (as defined below), the following transactions shall occur (such transactions in this Section 1, the
“Exchange”):

 

1.1       As
of the Closing Date (as defined below), the Exchange Note shall be free and clear of all Liens. Upon receipt of the Preferred Shares
in accordance with Section 1.2, all of the Investor’s rights under the Exchange Note shall be extinguished (including, without
limitation, the rights to receive any accrued and unpaid interest thereon or any other shares of Common Stock with respect thereto).

 

1.2       On
the Closing Date, the Company shall issue the Preferred Shares to the Investor (or its designee). Promptly after the Closing Date
the Company shall deliver a certificate evidencing the Preferred Shares to the Investor (or its designee). On the Closing Date,
the Investor shall be deemed for all corporate purposes to have become the holder of record of the Preferred Shares and shall have
the right to convert the Preferred Shares, irrespective of the date the Company delivers the certificate evidencing the Preferred
Shares to the Investor. For the avoidance of doubt, the Investor shall be entitled to exercise all of its rights with respect to
the Preferred Shares, including without limitation, the right to convert the Preferred Shares into Common Stock in accordance with
the terms of the Certificate of Designations, immediately following the Closing (as defined below), irrespective of when the certificate
for the Preferred Shares is delivered to the Investor.

 

    2 

     

    

 

1.3       The
Company and the Investor shall execute and/or deliver such other documents and agreements as are customary and reasonably necessary
to effectuate the Exchange.

 

2.       Voluntary
Reduction Notice; Waivers; Release; Leak-Out Amendment.

 

2.1       Voluntary
Reduction Notice. Effective as of the date the holders of 2015 Notes representing at least the Required Holders (as defined
in the 2015 Notes) shall have executed either this Agreement or an Other Agreement (the “Effective Date”), pursuant
to Section 7(d) of the 2015 Notes, the Company hereby elects to lower (but in no event increase) the Conversion Price of each of
the 2015 Notes of the Investor and each Other Investor with respect to any given Trading Day during the period (the “Voluntary
Reduction Period”, and any such reduction, each a “Voluntary Reduction”) commencing on the Effective
Date, through and including November 17, 2016, to the Alternate Conversion Price (as defined below) for such Trading Day. For the
purpose of this Section 2.1, the “Alternate Conversion Price” for any given Trading Day during the Voluntary
Reduction Period shall equal 85% of the lowest daily Weighted Average Price of the Common Stock during the five (5) consecutive
Trading Days ending and including such given Trading Day (with all such determinations to be appropriately adjusted for any stock
split, stock dividend, stock combination, reclassification or other similar transaction during such applicable period).

 

2.2       Waivers

 

(a)       Effective
as of the Effective Date, the Investor hereby waives any reduction in: (i) the exercise price of its 2015 Warrants pursuant to
Section 2(a) thereof, (ii) the exercise price of its 2016 Warrants pursuant to Section 2(a) thereof and (iii) the conversion price
of its 2016 Notes pursuant to Section 7(a) thereof, in each case, solely as a result of any Voluntary Reduction pursuant to Section
2.1 hereof.

 

(b)       Effective
as of the Effective Date, the Investor hereby elects pursuant to Section 8(d) of the 2015 Notes to defer the Installment Amount
with respect to the Investor's 2015 Notes with respect to the Installment Date occurring thereunder on November 30, 2016 until
the Installment Date of December 30, 2016 (including, without limitation, any rights to receive pre-delivery of shares of Common
Stock with respect to such Installment Amount on or prior to December 1, 2016).

 

(c)       Effective
as of the Effective Date, the 2015 Notes are hereby amended to add a new Section 8(g) at the end of Section 8 of the 2015 Notes
that provides as follows:

 

"(g)       October
31, 2016 Installment Date. Notwithstanding Section 8(d) to the contrary, the portion of the Installment Amount due on the October
31, 2016 Installment Date equal to the product obtained by multiplying (x) the number of Pre-Installment Conversion Shares delivered
by the Company to the Holder with respect to such Installment Date and (y) the Company Conversion Price as in effect on such Installment
Date, shall not be allowed to be deferred by the Holder to a later Installment Date."

 

    3 

     

    

 

(d)       Effective
as of the Effective Date, the Investor waives any right pursuant to Section 8(e) of the 2015 Notes to deliver any Acceleration
Notice during the period commencing on the Effective Date and ending on December 1, 2016, inclusive, with respect to the Installment
Amount due on the November 30, 2016 Installment Date.

 

(e)       Effective
as of the Effective Date, the Investor hereby waives the notice provisions Section 4(n) of each SPA, solely with respect to the
transactions contemplated by this Agreement and each Other Agreement (the “Right of Participation Waiver”).

 

(f)       So
long as any Preferred Shares of the Investor remains outstanding, the Company shall reserve the Initial Required Reserve Amount
(as defined below) of shares of Common Stock for conversion of the Preferred Shares of the Investor. Except for such obligation
to reserve the Initial Required Reserve Amount in accordance with the immediately preceding sentence, effective as of the Effective
Date, the Investor hereby waives any obligation of the Company to reserve shares of Common Stock with respect to any securities
of the Company held by the Holder pursuant to the Transaction Documents (as defined in the 2015 SPA), the Transaction Documents
(as defined in the 2016 SPA) or this Agreement. Except for such reservation of shares of Common Stock set forth on Schedule
2.2(f) attached hereto, the Initial Required Reserve Amount (together with the Initial Required Reserve Amount (as defined
in each Other Agreement) of each Other Investor pursuant to each Other Agreement), in the aggregate, represents all authorized,
but unissued shares of Common Stock as of the Closing Date.

 

(g)       Effective
as of the Effective Date, the Investor hereby waives any restriction or other prohibition on the Company consummating a reverse
share split of the Common Stock of the Company with respect to any securities of the Company held by the Holder pursuant to the
Transaction Documents (as defined in the 2015 SPA), the Transaction Documents (as defined in the 2016 SPA) or this Agreement.

 

2.3       Release.
On the Closing Date the Investor shall cause all amounts held in such Investor’s Holder Master Restricted Account with respect
to the 2015 Notes to be transferred to the operating account of the Company, in each case, pursuant to written instructions provided
by the Company [INSERT IN HUDSON BAY AGREEMENT ONLY: (less the Investor Counsel Expense (as defined below), which shall be released
to Schulte Roth & Zabel LLP))].

 

2.4       Leak-Out
Amendment. As of the Effective Date the Leak-Out Agreement is hereby amended as follows:

 

(a)       Notwithstanding
anything in the Leak-Out Agreement to the contrary, the Restricted Period (as defined in the Leak-Out Agreement) shall hereby be
extended from and including November 1, 2016 through and ending and including November 30, 2016.

 

    4 

     

    

 

3.       The Closing(s).
Subject to the conditions set forth below, the Exchange shall take place at the offices of Kelley Drye & Warren LLP, 101 Park
Avenue, New York, NY 10178, on the Effective Date, or at such other time and place as the Company and the Investor mutually agree
(the “Closing” and the “Closing Date”).

 

4.       Closing Conditions.

 

4.1       Condition’s
to Investor’s Obligations. The obligation of the Investor to consummate the Exchange is subject to the fulfillment, to
the Investor’s reasonable satisfaction, prior to or at the Closing, of each of the following conditions:

 

(a)        Representations
and Warranties(b). The representations and warranties of the Company contained in this Agreement shall be true and
correct in all material respects (except for those representations and warranties that are qualified by materiality or
Material Adverse Effect, which are accurate in all respects) on the date hereof and on and as of the Closing Date as if made
on and as of such date (except for representations and warranties that speak as of a specific date, which are accurate in all
material respects (except for those representations and warranties that are qualified by materiality or Material Adverse
Effect, which are accurate in all respects) as of such specified date).

 

(c)       Issuance
of Securities(d). At the Closing, the Company shall issue the Preferred Shares on the books and records of the
Company.

 

(e)       No
Actions(f). No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or
proposed before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit or obtain
substantial damages in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.

 

(g)       Proceedings and
Documents(h). All proceedings in connection with the transactions contemplated hereby and all documents and instruments
incident to such transactions shall be satisfactory in substance and form to the Investor, and the Investor shall have received
all such counterpart originals or certified or other copies of such documents as they may reasonably request.

 

(i)       No
Event of Default. On each Trading Day during the twenty (20) Trading Days immediately preceding the Closing Date, no Event
of Default or event that with the passage of time or giving of notice would constitute an Event of Default shall have occurred
(unless waived in writing by the Required Holders (as defined in the 2015 Notes)).

 

(j)       Minimum
Volume. Unless waived in writing by the Required Holders (as defined in the 2015 Notes), the quotient of (x) the sum of each
daily dollar trading volume of the Common Stock as reported by Bloomberg for each Trading Day during the twenty (20) consecutive
Trading Days immediately preceding the Closing Date, divided by (y) twenty (20) shall be at least $300,000.

 

    5 

     

    

 

(k)       Listing.
On each Trading Day during the twenty (20) Trading Days immediately preceding the Closing Date, the Common Stock (I) shall be designated
for quotation or listed on an Eligible Market and (II) shall not have been suspended.

 

(l)       No
Material Non-Public Information. As of the Closing Date, the Investor shall not be in possession of any material, nonpublic
information received from the Company, any Subsidiary or its respective agents or Affiliates.

 

(m)       No
Public Information Failure. As of the Closing Date, the Company shall have no knowledge of any fact that would cause any Preferred
Shares or Preferred Conversion Shares (without regard to any restriction or limitation on conversion of the Preferred Shares),
not to be eligible for resale pursuant to (i) Rule 144 without any volume limitation by the Investor (including, without limitation,
by virtue of an existing or expected Public Information Failure) or (ii) any applicable state securities laws.

 

(n)       Certificate
of Designations. As of the Closing Date, the Certificate of Designations shall have been filed with the Secretary of State
of Delaware and shall be in full force and effect.

 

4.2       Condition’s
to the Company’s Obligations. The obligation of the Company to consummate the Exchange is subject to the fulfillment,
to the Company’s reasonable satisfaction, prior to or at the Closing in question, of each of the following conditions:

 

(a)       Representations and
Warranties(b). The representations and warranties of the Investor contained in this Agreement shall be true and correct
in all material respects (except for those representations and warranties that are qualified by materiality or material adverse
effect, which are accurate in all respects) on the date hereof and on and as of the Closing Date as if made on and as of such date
(except for representations and warranties that speak as of a specific date, which are accurate in all material respects (except
for those representations and warranties that are qualified by materiality or material adverse effect, which are accurate in all
respects) as of such specified date).

 

(b)       Waiver.
The Company shall have obtained the waiver of the Right of Participation Waiver of the Investor and all Other Investors.

 

(c)       No
Actions. No action, proceeding, investigation, regulation or legislation shall have been instituted, threatened or proposed
before any court, governmental agency or authority or legislative body to enjoin, restrain, prohibit, or obtain substantial damages
in respect of, this Agreement or the consummation of the transactions contemplated by this Agreement.

 

(d)       Proceedings
and Documents. All proceedings in connection with the transactions contemplated hereby and all documents and instruments incident
to such transactions shall be satisfactory in substance and form to the Company and the Company shall have received all such counterpart
originals or certified or other copies of such documents as the Company may reasonably request.

 

    6 

     

    

 

5.1       Representations
and Warranties of the Company. The Company hereby represents and warrants to Investor that:

 

5.1       Organization, Good
Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which
the failure to so qualify would have a Material Adverse Effect (as defined below) on its business or properties. As used in this
Agreement, “Material Adverse Effect” means any material adverse effect on the business, properties, assets,
liabilities, operations, results of operations, condition (financial or otherwise) or prospects of the Company and its Subsidiaries,
if any, individually or taken as a whole, or on the transactions contemplated hereby or on the Transaction Documents (as defined
below) or by the agreements and instruments to be entered into (or entered into) in connection herewith or therewith, or on the
authority or ability of the Company to perform its obligations under this Agreement or the Transaction Documents.

 

5.2       Authorization.
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Agreement and the other Transaction Documents and the performance of all obligations of the Company hereunder
and thereunder, and the authorization of the Exchange, the issuance (and reservation for issuance) of the Preferred Shares and
the Preferred Conversion Shares (collectively, the “Securities”) have been taken on or prior to the date hereof.
The Certificate of Designations has been validly filed with the Secretary of State of Delaware and, as of the date hereof and the
Closing Date, remains in full force and effect.

 

5.3       Valid Issuance of
the Securities. The Preferred Shares when issued and delivered in accordance with the terms of this Agreement, for the consideration
expressed herein, and the Preferred Conversion Shares when issued in accordance with the terms of the Certificate of Designations,
for the consideration expressed therein, will be duly and validly issued, fully paid and non-assessable. Upon conversion of the
Preferred Shares, the Preferred Conversion Shares are freely tradable and shall not be required to bear any 1933 Act or other restrictive
legend. The Company agrees to take all actions, including, without limitation, the issuance by its legal counsel of any necessary
legal opinions, necessary to issue unrestricted Preferred Conversion Shares that are freely tradable on the principal Eligible
Market on which the Common Stock then trades without restriction and not containing any restrictive legend without the need for
any action by the Investor. As of the Closing, such aggregate number of shares of Common Stock set forth on the signature page
of the Investor (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction occurring
after the date hereof) (the "Initial Required Reserve Amount") shall have been duly authorized and reserved for
issuance of Common Stock with respect to the Investor's Preferred Shares.

 

5.4       Offering. Neither
the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation
or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. The Company
shall be responsible for the payment of any placement agent's fees, financial advisory fees, or brokers' commissions (other than
for persons engaged by the Investor or its investment advisor) relating to or arising out of the transactions contemplated hereby,
including, without limitation, placement agent fees payable to ROTH Capital Partners, LLC, as placement agent (the "Placement
Agent") in connection with the sale of the Securities. The Company shall pay, and hold the Investor harmless against,
any liability, loss or expense (including, without limitation, attorney's fees and out-of-pocket expenses) arising in connection
with any such claim. The Company acknowledges that it has engaged the Placement Agent in connection with the sale of the Securities.
Other than the Placement Agent, neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent
in connection with the sale of the Securities. The offer and issuance of the Securities as contemplated by this Agreement are exempt
from the registration requirements of the 1933 Act and the qualification or registration requirements of state securities laws
or other applicable blue sky laws. Neither the Company nor any authorized agent acting on its behalf will take any action hereafter
that would cause the loss of such exemptions.

 

    7 

     

    

 

5.5       Compliance With Laws.
The Company has not violated any law or any governmental regulation or requirement which violation has had or would reasonably
be expected to have a Material Adverse Effect, and the Company has not received written notice of any such violation.

 

5.6       Consents; Waivers.
No consent, waiver, approval or authority of any nature, or other formal action, by any Person, not already obtained, is required
in connection with the execution and delivery of this Agreement by the Company or the consummation by the Company of the transactions
provided for herein and therein.

 

5.7       Acknowledgment Regarding
Investor’s Purchase of Securities. The Company acknowledges and agrees that the Investor is acting solely in the capacity
of arm’s length purchaser with respect to this Agreement and the other documents entered into in connection herewith (collectively,
the “Transaction Documents”) and the transactions contemplated hereby and thereby and that the Investor is not
(i) an officer or director of the Company, (ii) an “affiliate” of the Company (as defined in Rule 144 promulgated under
the 1933 Act), or (iii) to the knowledge of the Company, a “beneficial owner” of more than 10% of the shares of Common
Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Company further acknowledges that the Investor is not acting
as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the
transactions contemplated hereby and thereby, and any advice given by the Investor or any of its representatives or agents in connection
with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Investor’s
acceptance of the Preferred Shares. The Company further represents to the Investor that the Company’s decision to enter into
the Transaction Documents has been based solely on the independent evaluation by the Company and its representatives.

 

5.8       Absence of Litigation.
Except as set forth in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court,
public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against
or affecting the Company, the Common Stock, the Exchange Note or any of the Company’s officers or directors in their capacities
as such.

 

    8 

     

    

 

5.9       No
Group. The Company acknowledges that, to the Company’s knowledge, the Investor is acting independently in connection
with this Agreement and the transactions contemplated hereby, and is not acting as part of a “group” as such term is
defined under Section 13(d) of the 1933 Act and the rules and regulations promulgated thereunder.

 

5.10       Validity;
Enforcement; No Conflicts. This Agreement and each Transaction Document to which the Company is a party have been duly and
validly authorized, executed and delivered on behalf of the Company and shall constitute the legal, valid and binding obligations
of the Company enforceable against the Company in accordance with their respective terms, except as such enforceability may be
limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. The execution,
delivery and performance by the Company of this Agreement and each Transaction Document to which the Company is a party and the
consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational
documents of the Company or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both
would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Company is a party or by which it is bound, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities or “blue sky” laws) applicable to the
Company, except in the case of clause (ii) above, for such conflicts, defaults or rights which would not, individually or in the
aggregate, reasonably be expected to result in a Material Adverse Effect.

 

5.11       Disclosure.
Other than as set forth in the 8-K Filing (as defined below), the Company confirms that neither it nor any other Person acting
on its behalf has provided the Investor or its agents or counsel with any information that constitutes or could reasonably be expected
to constitute material, nonpublic information. The Company understands and confirms that the Investor will rely on the foregoing
representations in effecting transactions in the Exchange Securities.

 

5.12       Capitalization.
As of the date hereof, the Company has 95,083,052 shares of Common Stock issued and outstanding.

 

6.       Representations
and Warranties of the Investor. The Investor hereby represents, warrants and covenants that:

 

Authorization.
The Investor has full power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate
the transactions contemplated hereby and has taken all action necessary to authorize the execution and delivery of this Agreement,
the performance of its obligations hereunder and the consummation of the transactions contemplated hereby.

 

    9 

     

    

 

6.2       Accredited Investor
Status; Investment Experience. The Investor is an “accredited investor” as that term is defined in Rule 501(a)
of Regulation D. The Investor can bear the economic risk of its investment in the Securities, and has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risks of an investment in the Securities.

 

6.3       No Governmental Review.
The Investor understands that no United States federal or state agency or any other government or governmental agency has passed
on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities
nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

6.4       Validity; Enforcement;
No Conflicts. This Agreement and each Transaction Document to which the Investor is a party have been duly and validly authorized,
executed and delivered on behalf of the Investor and shall constitute the legal, valid and binding obligations of the Investor
enforceable against the Investor in accordance with their respective terms, except as such enforceability may be limited by general
principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating
to, or affecting generally, the enforcement of applicable creditors’ rights and remedies. The execution, delivery and performance
by the Investor of this Agreement and each Transaction Document to which the Investor is a party and the consummation by the Investor
of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Investor
or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which the Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
federal and state securities or “blue sky” laws) applicable to the Investor, except in the case of clause (ii) above,
for such conflicts, defaults or rights which would not, individually or in the aggregate, reasonably be expected to have a material
adverse effect on the ability of the Investor to perform its obligations hereunder.

 

6.5       Ownership
of Original Note. The Investor owns and holds, beneficially and of record, the entire right, title, and interest in and to
the Exchange Note free and clear of all rights and Liens (other than pledges or security interests (x) arising by operation of
applicable securities laws and (y) that the Investor may have created in favor of a prime broker under and in accordance with its
prime brokerage agreement with such broker). The Investor has full power and authority to transfer and dispose of the Exchange
Note to the Company free and clear of any right or Lien. Other than the transactions contemplated by this Agreement, there is no
outstanding vote, plan, pending proposal, or other right of any Person to acquire all or any part of the Exchange Note or any shares
of Common Stock issuable upon conversion of the Exchange Note.

 

    10 

     

    

 

7.       Additional
Covenants 

 

7.1       Disclosure.
The Company shall, on or before 8:30 a.m., New York City time, on the first business day after the date of this Agreement, issue
a press release and Current Report on Form 8-K disclosing all material terms of the transactions contemplated hereby and attaching
the form of this Agreement as an exhibit thereto (collectively with all exhibits attached thereto, the “8-K Filing”).
From and after the issuance of the 8-K Filing, the Investor shall not be in possession of any material, nonpublic information received
from the Company or any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents, that
is not disclosed in the 8-K Filing. The Company shall not, and shall cause its officers, directors, employees, affiliates and agents,
not to, provide the Investor with any material, nonpublic information regarding the Company from and after the filing of the 8-K
Filing without the express written consent of the Investor. To the extent that the Company delivers any material, non-public information
to the Investor without the Investor's express prior written consent, the Company hereby covenants and agrees that the Investor
shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors,
employees, affiliates or agent with respect to, or a duty to the to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, affiliates or agent or not to trade on the basis of, such material, non-public information. The
Company shall not disclose the name of the Investor in any filing, announcement, release or otherwise, unless such disclosure is
required by law or regulation. In addition, effective upon the filing of the 8-K Filing, the Company acknowledges and agrees that
any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its
subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Investor
or any of its affiliates, on the other hand, shall terminate and be of no further force or effect. The Company understands and
confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company.

 

7.2       Listing.
The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the Preferred Conversion Shares
upon each Eligible Market upon which the Common Stock is then listed or designated for quotation (as applicable) (subject to official
notice of issuance) and shall maintain such listing of all the Preferred Conversion Shares from time to time issuable under the
terms of the Transaction Documents. The Company shall pay all fees and expenses in connection with satisfying its obligations under
this Section 7.2.

 

7.3       Holding
Period. For the purposes of Rule 144 of the 1933 Act, the Company acknowledges that (i) the holding period of the Exchange
Note may be tacked onto the holding period of the Preferred Shares (and upon conversion of the Preferred Shares, the Preferred
Conversion Shares) and (ii) the holding period of the Preferred Shares may be tacked onto the holding period of the Preferred Conversion
Shares, and the Company agrees not to take a position contrary to this Section 7.3.

 

    11 

     

    

 

7.4       Blue
Sky. The Company shall make all filings and reports relating to the Exchange required under applicable securities or “Blue
Sky” laws of the states of the United States following the date hereof, if any.

 

7.5       Fees
and Expenses. [INSERT IN HUDSON BAY AGREEMENT ONLY: The Company shall reimburse the Investor for its legal fees and expenses
in connection with the preparation and negotiation of this Agreement and transactions contemplated thereby, in an amount not to
exceed $8,000, which the Investor may withhold from the cash released to the Company from the Investor's Holder Master Restricted
Account on or prior to the Effective Date pursuant to Section 2.3(i) (the “Investor Counsel Expense”). The Investor
Counsel Expense shall be paid by the Company whether or not the transactions contemplated by this Agreement are consummated.] Except
as otherwise set forth above, each party to this Agreement shall pay the fees and expenses of its advisers, counsel, accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery
and performance of this Agreement.

 

7.6       Officer’s
Certificate. At any time the Preferred Shares remain outstanding, with respect to any record date of any stockholder meeting
of the Company, if requested by the Company in writing, the Holder shall deliver to the Company, no later than the second (2nd)
Business Day after such request, a certificate, signed by an authorized officer of the Holder, certifying to the number of shares
of Common Stock held by such Holder and its Attribution Parties as of such record date for such meeting of shareholders.

 

8.       Miscellaneous

 

8.1       Successors and Assigns.
Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon
the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

8.2       Governing Law; Jurisdiction;
Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision
or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state or federal courts
sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE,
AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

    12 

     

    

 

8.3       Titles and Subtitles.
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

8.4       Notices. Any notices,
consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing
and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party) or by
electronic mail; or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to
the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

 

If to the Company:

 

Great Basin Scientific,
Inc.

2441 South 3850 West

Salt Lake City, UT 84120

Telephone: (801) 990-1055 ext. 112

Facsimile: (801) 990-1051

Attention: Jeff Rona

 

With a copy to:

 

Dorsey & Whitney
LLP

1400 Wewatta Street, Suite 400

Denver, CO 80202

Telephone: (303) 352-1133

Facsimile: (303) 629-3450

Attention: Jason K. Brenkert, Esq.

Email: brenkert.jason@dorsey.com

 

and

 

Kelley Drye &
Warren LLP

101 Park Avenue

New York, NY 10178

Telephone: 212-808-7540

Facsimile: (212) 808-7897

Attention: Michael Adelstein, Esq.

Email: madelstein@kelleydrye.com

 

    13 

     

    

 

If to the Investor, to
its address, facsimile number and e-mail address set forth on its signature page hereto,

 

or to such other address,
facsimile number and/or e-mail address and/or to the attention of such other Person as the recipient party has specified by written
notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given
by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s
facsimile machine or e-mail containing the time, date, recipient facsimile number and an image of the first page of such transmission
or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt
from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

8.5       Finder’s Fees.
Each party represents that it neither is nor will be obligated for any finders’ fee or commission in connection with this
transaction (excluding any fees required to be paid by the Company to Roth Capital Partners, LLC in connection with the original
Transaction Documents). The Company shall indemnify and hold harmless the Investor from any liability for any commission or compensation
in the nature of a finders’ fee (and the costs and expenses of defending against such liability or asserted liability) for
which the Company or any of its officers, employees or representatives is responsible.

 

8.6       Amendments and Waivers.
Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in
a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investor.

 

8.7       Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms so long as this Agreement as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s)
in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close
as possible to that of the prohibited, invalid or unenforceable provision(s).

 

8.8       Entire Agreement.
This Agreement together with the Leak-Out Agreement, represents the entire agreement and understandings between the parties concerning
the Exchange and the other matters described herein and therein and supersedes and replaces any and all prior agreements and understandings
solely with respect to the subject matter hereof and thereof. Notwithstanding anything herein to the contrary, nothing herein shall
amend, modify or waive any term or condition of the Leak-Out Agreement or of any of the other Transaction Documents (as defined
in each of the SPAs) (other than the 2015 Notes, which shall be cancelled following the consummation of the Exchange pursuant to
Section 1.1).

 

    14 

     

    

 

8.9       Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

8.10       Interpretation.
Unless the context of this Agreement clearly requires otherwise, (a) references to the plural include the singular, the singular
the plural, the part the whole, (b) references to any gender include all genders, (c) “including” has the inclusive
meaning frequently identified with the phrase “but not limited to” and (d) references to “hereunder” or
“herein” relate to this Agreement.

 

8.11       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

8.12       Survival.
The representations, warranties and covenants of the Company and the Investor contained herein shall survive the Closing and delivery
of the Securities.

 

8.13       Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

8.14       No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

8.15       Independent
Nature of Investor's Obligations and Rights. The obligations of the Investor under this Agreement are several and not joint
with the obligations of any Other Investor, and the Investor shall not be responsible in any way for the performance of the obligations
of any Other Investor under any Other Agreement. Nothing contained herein or in any Other Agreement, and no action taken by the
Investor pursuant hereto, shall be deemed to constitute the Investor and Other Investors as a partnership, an association, a joint
venture or any other kind of entity, or create a presumption that the Investor and Other Investors are in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated by this Agreement or any Other Agreement and the
Company acknowledges that, to the best of its knowledge, the Investor and the Other Investors are not acting in concert or as a
group with respect to such obligations or the transactions contemplated by this Agreement or any Other Agreement. The Company and
the Investor confirm that the Investor has independently participated in the negotiation of the transactions contemplated hereby
with the advice of its own counsel and advisors. The Investor shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any Other Investor to
be joined as an additional party in any proceeding for such purpose.

 

    15 

     

    

 

8.16       Equal
Treatment Acknowledgement; Most Favored Nations. The parties hereto herby acknowledge and agree that, in accordance with Section
9(e) of each SPA, the Company is obligated to present the terms of this offering to each Other Investor; provided that each Other
Agreement shall be negotiated separately with each Other Investor and shall not in any way be construed as the Investor or any
Other Investor acting in concert or as a group with respect to the purchase, disposition or voting of securities of the Company
or otherwise. The Company hereby represents and warrants as of the date hereof and covenants and agrees that none of the terms
offered to any Person with respect to the Exchange, including, without limitation with respect to any consent, release, amendment,
settlement, or waiver relating to the Exchange (each an “Exchange Document”), is or will be more favorable to
such Person than those of the Investor and this Agreement. If, and whenever on or after the date hereof, the Company enters into
an Exchange Document, then (i) the Company shall provide notice thereof to the Investor immediately following the occurrence thereof
and (ii) the terms and conditions of this Agreement shall be, without any further action by the Investor or the Company, automatically
amended and modified in an economically and legally equivalent manner such that the Investor shall receive the benefit of the more
favorable terms and/or conditions (as the case may be) set forth in such Exchange Document, provided that upon written notice to
the Company at any time the Investor may elect not to accept the benefit of any such amended or modified term or condition, in
which event the term or condition contained in this Agreement shall apply to the Investor as it was in effect immediately prior
to such amendment or modification as if such amendment or modification never occurred with respect to the Investor. The provisions
of this Section 8.16 shall apply similarly and equally to each Exchange Document.

 

[SIGNATURES ON THE FOLLOWING
PAGE]

 

    16 

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	THE COMPANY
	 	 	 
	 	GREAT BASIN SCIENTIFIC, INC.
	 	 	 
	 	 	 
	 	By:  	 
	 	 	Name:
	 	 	Title:

 

     

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be duly executed and delivered as of the date provided above.

 

	 	INVESTOR:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	By: 	 
	 		Name:
	 		Title:
	 	 	 
	 	 	 
	 	Address for Notices:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	Fax#:	 
	 	 	 
	 	SSN#: 	 
	 	 	 
	 	Number of Preferred Shares:
	 	 	 
	 	Initial Required Reservation Amount:
	 	 	 

 

	 	Maximum Percentage: 	 

 

     

     

    

 

EXHIBIT A

 

 

Certificate of Designations.

 

 

[See attached]

 

     

     

    

 

Schedule 2.2(f)

 

Other Shares of Common Stock Reserved

 

Total of 38,654 shares of Common Stock reserved
(including 38,438 shares of Common Stock reserved with respect to the Series G Warrants outstanding as of the date hereof)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]